Prime

Type your tag names separated by a space and hit enter

Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy.

Abstract

BACKGROUND AND AIM

There have been no reports comparing the therapeutic results of adefovir (ADV) and entecavir (ETV) rescue therapy for patients with lamivudine (LAM)-resistant chronic hepatitis B (CHB). We aimed to compare the cumulative efficacy and resistance of ETV 1.0 mg monotherapy, ADV monotherapy and ADV add-on LAM combination therapy in LAM-refractory patients.

METHODS

One hundred and four patients were included in the following three treatment groups; group 1 (n = 24), LAM was switched to ETV (1.0 mg once a day); group 2 (n = 44), LAM was switched to ADV (10 mg once a day); and group 3 (n = 36), ADV was added to LAM (10 mg once a day).

RESULTS

After 6 months of rescue treatment, alanine aminotransferase normalization was observed in 75.0%, 65.9% and 74.3% of patients receiving ETV monotherapy, ADV monotherapy and ADV add-on therapy, respectively. A significantly higher log(10)HBV-DNA drop at 6 months occurred in the ADV add-on group compared with the ETV group. The rate of HBV-DNA polymerase chain reaction undetectability (<300 copies/mL) 6 months after initiation of ETV monotherapy, ADV monotherapy and ADV add-on therapy was 33.3%, 27.3% and 68.6%, respectively (P = 0.003). The cumulative HBeAg seroconversion rate was significantly higher in ADV add-on/ADV monotherapy groups compared with the ETV monotherapy group (P = 0.022). Viral breakthrough and genotypic resistance were detected in six (25.0%) and six (13.6%) patients in the ETV and ADV monotherapy groups, whereas no cases of genotypic resistance were detected in ADV add-on group 24 months after initiation of antiviral treatment (P < 0.01).

CONCLUSION

Adefovir add-on treatment in patients with LAM-resistant CHB suppresses HBV replication more effectively than ETV or ADV monotherapy. Additionally, no genotypic resistance was detected in the ADV add-on group.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University, Jongro-Ku, Seoul, Korea. hongjoo3.kim@samsung.com

    , , , , ,

    Source

    MeSH

    Adenine
    Adult
    Alanine Transaminase
    Antiviral Agents
    Biological Markers
    DNA, Viral
    Drug Resistance, Viral
    Drug Therapy, Combination
    Female
    Genotype
    Guanine
    Hepatitis B e Antigens
    Hepatitis B virus
    Hepatitis B, Chronic
    Humans
    Lamivudine
    Male
    Middle Aged
    Organophosphonates
    Republic of Korea
    Retrospective Studies
    Time Factors
    Treatment Outcome
    Viral Load
    Virus Replication

    Pub Type(s)

    Comparative Study
    Journal Article
    Research Support, Non-U.S. Gov't

    Language

    eng

    PubMed ID

    20659226

    Citation

    TY - JOUR T1 - Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy. AU - Kim,Hong Joo, AU - Park,Jung Ho, AU - Park,Dong Il, AU - Cho,Yong Kyun, AU - Sohn,Chong Il, AU - Jeon,Woo Kyu, AU - Kim,Byung Ik, PY - 2010/7/28/entrez PY - 2010/7/28/pubmed PY - 2010/11/16/medline SP - 1374 EP - 80 JF - Journal of gastroenterology and hepatology JO - J. Gastroenterol. Hepatol. VL - 25 IS - 8 N2 - BACKGROUND AND AIM: There have been no reports comparing the therapeutic results of adefovir (ADV) and entecavir (ETV) rescue therapy for patients with lamivudine (LAM)-resistant chronic hepatitis B (CHB). We aimed to compare the cumulative efficacy and resistance of ETV 1.0 mg monotherapy, ADV monotherapy and ADV add-on LAM combination therapy in LAM-refractory patients. METHODS: One hundred and four patients were included in the following three treatment groups; group 1 (n = 24), LAM was switched to ETV (1.0 mg once a day); group 2 (n = 44), LAM was switched to ADV (10 mg once a day); and group 3 (n = 36), ADV was added to LAM (10 mg once a day). RESULTS: After 6 months of rescue treatment, alanine aminotransferase normalization was observed in 75.0%, 65.9% and 74.3% of patients receiving ETV monotherapy, ADV monotherapy and ADV add-on therapy, respectively. A significantly higher log(10)HBV-DNA drop at 6 months occurred in the ADV add-on group compared with the ETV group. The rate of HBV-DNA polymerase chain reaction undetectability (<300 copies/mL) 6 months after initiation of ETV monotherapy, ADV monotherapy and ADV add-on therapy was 33.3%, 27.3% and 68.6%, respectively (P = 0.003). The cumulative HBeAg seroconversion rate was significantly higher in ADV add-on/ADV monotherapy groups compared with the ETV monotherapy group (P = 0.022). Viral breakthrough and genotypic resistance were detected in six (25.0%) and six (13.6%) patients in the ETV and ADV monotherapy groups, whereas no cases of genotypic resistance were detected in ADV add-on group 24 months after initiation of antiviral treatment (P < 0.01). CONCLUSION: Adefovir add-on treatment in patients with LAM-resistant CHB suppresses HBV replication more effectively than ETV or ADV monotherapy. Additionally, no genotypic resistance was detected in the ADV add-on group. SN - 1440-1746 UR - https://www.unboundmedicine.com/medline/citation/20659226/Rescue_therapy_for_lamivudine_resistant_chronic_hepatitis_B:_comparison_between_entecavir_1_0_mg_monotherapy_adefovir_monotherapy_and_adefovir_add_on_lamivudine_combination_therapy_ L2 - http://dx.doi.org/10.1111/j.1440-1746.2010.06381.x ER -